ALL-287: Acute Lymphoblastic Leukemia: Clinical Characteristics and Survival in a Private Health Care Program Population in Argentina

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 21; p. S274
• Main Authors: Patino, Ana Flavia, Makiya, Monica, Conca, Alberto Gimenez, Perusini, Maria Agustina
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-09-2021
• Subjects: acute lymphoblastic leukemia; ALL; clinical features; survival; ALL; acute lymphoblastic leukemia; clinical features; survival
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(21)01662-1

Acute lymphoblastic leukemia (ALL) comprises <1% of adult cancers and represents the most common childhood malignancy. Childhood leukemia survival is better than that of adults, with 5-year survival rate >85% compared to 50%. Available ALL data is mainly from pediatric populations in European countries and the United States. Argentinian data is scarce.
Describe clinical characteristics and survival in ALL patients.
Retrospective cohort study between January 1, 2010, and December 31, 2019.
The study was conducted at Hospital Italiano de Buenos Aires.
All adult and pediatric patients in the Italian Hospital Medical Program with ALL according to WHO criteria were included.
Survival time was estimated one year from diagnosis, expressed as one-year follow-up. Fatality rate was calculated as incident cases per 100 person-years. An age-stratified analysis was performed.
22 patients with ALL were included. The median age at diagnosis was 43.22 years (IQR: 10.35–75.45), 54.55% were male. Considering the WHO classification, 18 (81.82%) were ALL not otherwise specified. By immunophenotype, 16 (72.73%) corresponded to common B-ALL. Chromosome Ph-positive was seen in 13.64%. Complex karyotype only occurred in the adult subgroup (18 years or older). In stratified analysis, 36.36% of patients were diagnosed younger than 18 years (pediatric population), and 31.81% of patients were diagnosed at age 65 years or older (adult population). Only 1 patient was in the AYA subgroup (15–40 years). The median follow-up for the pediatric population was 6.74 years (IQR: 4.42–9.54) vs 1.08 years (IQR: 0.84–1.97) in adults. The fatality rate in pediatric cases was 18 per 100 person-years (95% CI: 0.2–13) vs 44.65 (95% CI: 23.23–85.81) in adults. Only one patient died among those younger than 17 years vs 9 (64.28%) among those older than 18 years. All patients up to 17 years of age were alive at one-year follow-up, unlike adults, who had a one-year survival rate of 64% (95% CI 34%–83%).
Our outcomes are similar to data in the literature, with a better prognosis and survival among the population aged 17 years or younger. We do not have data on patients in the AYA subgroup.